Finding. A de novo MFN2 p.N311S in the GTPase domain appeared in one dilated-cardiomyopathy patient. Models predict a badly distorted fold and a weaker handshake with Parkin. In H9c2 cardiomyoblasts the mutant protein is unstable, mitochondria clump and fragment, membrane potential, ATP and oxygen consumption fall, calcium and ROS rise, and a hypertrophic transcriptional program turns on.
Why this paper matters
MFN2 disease is usually Charcot–Marie–Tooth. Heart phenotypes exist but are under-assigned. Gupta, Mukhopadhyay, Yadav, Jain and Mohapatra put a rare GTPase-domain missense on a DCM workup and then did the functional work that most WES papers skip.
The genetics are thin and should be said plainly: 15 DCM genomes, one de novo allele, vanishingly rare in gnomAD, absent from local controls. That is a candidate, not a gene-discovery. The reason the paper is in this corpus is the organelle phenotype.
What the cell biology shows
Stable mutant H9c2 lines lose MFN2 protein, which already argues loss-of-function rather than a neat dominant gain. Remaining mitochondria cluster and fragment — the classic fusion-failure morphology. Bioenergetic collapse is broad (ΔΨm, ATP, OCR). Cytosolic Ca2+ and ROS rise, consistent with both failed quality control and failed ER–mitochondria tethering jobs that MFN2 also holds. Transcriptionally, PI3K/AKT/mTOR and hypertrophic markers (Myh6, Nppa, Nfatc1/c2) move in the direction a failing ventricle would.
The Parkin docking result is the most specific molecular claim. If N311S weakens MFN2–PRKN contact, the variant can injure fusion and mitophagy at once. That is still a prediction until someone measures Parkin recruitment and mitophagic flux.
How to score it
Importance is solid for mitochondrial dynamics in cardiomyopathy; confidence is medium because n=1 genetics plus a rat myoblast line can overstate pathogenicity. An RMSD of 8.95 Å from modeling is a red flag, not a structure. Do not write this up as “MFN2 causes DCM.” Write it as “N311S is a plausible LOF allele with a cardiomyocyte mitochondrial phenotype that deserves replication in iPSC-CMs and myocardium.”
What to take
For variant curators: add functional codes for protein instability, fragmentation, OCR loss, and predicted PRKN-interface damage. For mito-heart programs: this is another reason to sequence MFN2 in non-CMT DCM, especially de novo pediatric or young-adult cases. For agent pipelines: keep the assay list; discard any sentence that treats 15 WES cases as a cohort proof.